List of Zontivity drug patents
Zontivity is owned by Xspire Pharma.
Zontivity contains Vorapaxar Sulfate.
Zontivity has a total of 2 drug patents out of which 0 drug patents have expired.
Zontivity was authorised for market use on 08 May, 2014.
Zontivity is available in tablet;oral dosage forms.
Zontivity can be used as reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad), reduction of thrombotic cardiovascular events.
The generics of Zontivity are possible to be released after 23 December, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7713999 | XSPIRE PHARMA | Thrombin receptor antagonists |
May, 2024
(1 year, 2 months from now) | |
| US7304078 | XSPIRE PHARMA | Thrombin receptor antagonists |
Dec, 2027
(4 years from now) | |
Drugs and Companies using VORAPAXAR SULFATE ingredient
Market Authorisation Date: 08 May, 2014
Treatment: Reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (mi) or with peripheral arterial disease (pad); Reduction of thrombotic cardiovascular events
Dosage: TABLET;ORAL
ZONTIVITY family patents
18
United States
12
European Union
8
Japan
6
Norway
6
China
6
Korea, Republic of
6
Australia
5
Russia
5
Spain
5
Brazil
5
Argentina
5
Taiwan, Province of China
5
Hong Kong
5
South Africa
5
Canada
4
Germany
4
Malaysia
4
New Zealand
4
Austria
4
Mexico
4
Peru
4
Israel
4
Ecuador
3
Portugal
3
Cyprus
3
Slovenia
3
Denmark
2
Singapore
2
Poland
1
Colombia
1
Lithuania
1
Slovakia
1
Hungary
1
Luxembourg
1
Czech Republic
1
Chile
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic